Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
-0.39% $7.75
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 189.32 mill |
EPS: | -1.350 |
P/E: | -5.74 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 24.43 mill |
Avg Daily Volume: | 0.0401 mill |
RATING 2024-04-19 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -5.74 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -5.74 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
$-7.35 (-194.78%) $-15.10 |
Date: 2024-04-19 |
Expected Trading Range (DAY) |
---|
$ 7.36 - 8.14 ( +/- 5.05%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2012-12-20 | Hofer Michael | Sell | 40 000 | Patriot Minefinders Inc. |
2012-12-18 | Hofer Michael | Sell | 40 000 | Patriot Minefinders Inc. |
2012-06-19 | Tejada Fred | Buy | 500 000 | Common Shares |
2012-06-19 | Blanchet Justin | Buy | 500 000 | Common Shares |
2012-06-19 | Schweitzer John H. | Buy | 500 000 | Common Shares |
INSIDER POWER |
---|
0.00 |
Last 8 transactions |
Buy: 3 000 000 | Sell: 80 000 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.75 (-0.39% ) |
Volume | 0.0450 mill |
Avg. Vol. | 0.0401 mill |
% of Avg. Vol | 112.38 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.